title: [Complex treatment of breast cancer patients with brain metastases].
abstract: Brain metastases in breast cancer develop for 24-32 months after the detection of the primary tumor. The study included patients with brain metastases who were divided into three groups: the first group--with early chemoradiotherapy (CRT) without induction chemotherapy (IC) by capecitabine; the second group--with delayed CRT with 4 or 8 courses of IC by capecitabine; the third group (a historical control) who received only whole brain radiation therapy. The median time to progression of intracranial metastases was 15.3, 12 and 5 months, respectively. The median time to the intracranial progression significantly less in the third group (5 months) compared with the first (15.3 months) (p = 0.0007) and the second (12 months) (p = 0.027) groups. The overall survival rate was 22.1, 15.1 and 6.8 months in three groups, respectively.
authors.forename: S V
authors.initials: SV
authors.lastname: Medvedev
authors.forename: S I
authors.initials: SI
authors.lastname: Tkachev
authors.forename: E A
authors.initials: EA
authors.lastname: Moskvina
authors.forename: Z P
authors.initials: ZP
authors.lastname: Mikhina
authors.forename: D R
authors.initials: DR
authors.lastname: Naskhletashvili
authors.forename: P V
authors.initials: PV
authors.lastname: Bulychkin
authors.forename: D S
authors.initials: DS
authors.lastname: Romanov
authors.forename: O P
authors.initials: OP
authors.lastname: Trofimova
authors.forename: A V
authors.initials: AV
authors.lastname: Berdnik
authors.forename: Yu B
authors.initials: YB
authors.lastname: Bykova
authors.forename: R A
authors.initials: RA
authors.lastname: Gutnik
authors.forename: I P
authors.initials: IP
authors.lastname: Yazhgunovich
authors.forename: D I
authors.initials: DI
authors.lastname: Fedoseenko
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000069287:Capecitabine / Q000008:administration & dosage*; D059186:Chemoradiotherapy, Adjuvant; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D012426:Russia / Q000453:epidemiology; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000069287:Capecitabine